(Reuters) - Biotechnology company Biogen Idec Inc said U.S. health regulators extended by three months the review date of its much-awaited multiple sclerosis (MS) drug BG-12, but analysts said the delay was only a minor setback. Shares of Biogen were down 2 percent at $150.72 in morning trading on the Nasdaq. The stock has risen more than 50 percent over the past 12 months, largely on optimism about BG-12, which showed robust results in trials and had no safety concerns. Analysts said the delay would push the review date to March, but added such extensions were not uncommon. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment